|
RAPGEF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.73094871769308E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.35940197671425E-11 |
| Normal-vs-Stage2 |
3.597000E-04 |
| Normal-vs-Stage3 |
1.0037526365636E-12 |
| Normal-vs-Stage4 |
1.62625468647093E-12 |
| Stage1-vs-Stage2 |
8.780100E-02 |
| Stage1-vs-Stage3 |
3.691500E-02 |
| Stage1-vs-Stage4 |
2.05379999999034E-05 |
| Stage2-vs-Stage3 |
3.179800E-03 |
| Stage2-vs-Stage4 |
2.11310000000076E-05 |
| Stage3-vs-Stage4 |
4.772000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.75886038645513E-14 |
| Normal-vs-AfricanAmerican |
2.21149999999337E-05 |
| Normal-vs-Asian |
2.68569999573032E-09 |
| Caucasian-vs-AfricanAmerican |
5.969400E-01 |
| Caucasian-vs-Asian |
8.887800E-01 |
| AfricanAmerican-vs-Asian |
5.294200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.747780277929E-12 |
| Normal-vs-Female |
3.10329539843224E-12 |
| Male-vs-Female |
7.314000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.08050013380989E-10 |
| Normal-vs-Age(41-60Yrs) |
2.62309951537532E-10 |
| Normal-vs-Age(61-80Yrs) |
1.92512672470002E-12 |
| Normal-vs-Age(81-100Yrs) |
1.002410E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.391000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.632230E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.964200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.313400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.396400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.782800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.86400003712828E-09 |
| Classical-VS-Follicular |
1.834020E-02 |
| Classical-VS-Other |
3.057000E-01 |
| Classical-VS-Normal |
2.01028083068877E-12 |
| Tall-VS-Follicular |
6.15949957705197E-10 |
| Tall-VS-Other |
1.462440E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
1.150400E-01 |
| Follicular-VS-Normal |
1.815920E-04 |
| Other-VS-Normal |
3.185000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.72229996930895E-09 |
| Normal-vs-N1 |
6.61004584401326E-12 |
| N0-vs-N1 |
1.494440E-02 |
|
|
